title: Downregulation of the neonatal Fc receptor expression in non-small cell lung cancer tissue is associated with a poor prognosis.
abstract: Lung cancer is the leading cause of cancer-related death worldwide. Although the recommended tumor, node and metastasis (TNM) classification and stage determination are important to select therapeutic options for patients with non-small cell lung carcinoma (NSCLC), additional molecular markers are required to indicate the prognosis, in particular within a specific stage, and help with the management of patients.Because neonatal Fc receptor (FcRn) has recently been involved in colon cancer immunosurveillance, we measured its expression in non-cancerous and NSCLC lung tissues and evaluated its prognostic value in overall survival for patient with NSCLC. FcRn expression was determined at both mRNA and protein levels on cancerous and adjacent non-cancerous tissues from 80 NSCLC patients. In NSCLC, FcRn was mainly found in resident and tumor infiltrating immune cells. The corresponding mRNA and protein were significantly less abundant in lung tumor than non-cancerous tissue. Moreover, analysis of our cohort and datasets from the public data bases show that FCGRT mRNA down-regulation is a robust and independent, unfavorable predictive factor of NSCLC patient survival. We conclude that FCGRT mRNA expression may be a useful additional marker for immunoscoring, reflecting tumor immune system, and help in the decision-making process for NSCLC patients.
authors.affiliation: Université François Rabelais, UMR 1100,  Tours, France.|INSERM, Centre d'Etude des Pathologies Respiratoires, UMR 1100, Tours, France.
authors.forename: Emilie
authors.initials: E
authors.lastname: Dalloneau
authors.affiliation: Université François Rabelais de Tours, CNRS, GICC UMR 7292, Tours, France.
authors.forename: Nadine
authors.initials: N
authors.lastname: Baroukh
authors.affiliation: Department of Biochemistry and Molecular Biology, University of Athens, Panepistimiopolis, Athens, Greece.
authors.forename: Konstantinos
authors.initials: K
authors.lastname: Mavridis
authors.affiliation: Université François Rabelais, UMR 1100,  Tours, France.|INSERM, Centre d'Etude des Pathologies Respiratoires, UMR 1100, Tours, France.
authors.forename: Agnès
authors.initials: A
authors.lastname: Maillet
authors.affiliation: Université François Rabelais, UMR 1100,  Tours, France.|INSERM, Centre d'Etude des Pathologies Respiratoires, UMR 1100, Tours, France.
authors.forename: Fabien
authors.initials: F
authors.lastname: Gueugnon
authors.affiliation: Université François Rabelais, UMR 1100,  Tours, France.|INSERM, Centre d'Etude des Pathologies Respiratoires, UMR 1100, Tours, France.
authors.forename: Yves
authors.initials: Y
authors.lastname: Courty
authors.affiliation: Université François Rabelais, UMR 1100,  Tours, France.|INSERM, Centre d'Etude des Pathologies Respiratoires, UMR 1100, Tours, France.
authors.forename: Agnès
authors.initials: A
authors.lastname: Petit
authors.affiliation: Institute of Health and Biomedical Innovation, Translational Research Institute, Queensland University of Technology, Brisbane, Queensland, Australia.
authors.forename: Thomas
authors.initials: T
authors.lastname: Kryza
authors.affiliation: Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Montpellier, France.
authors.forename: Maguy
authors.initials: M
authors.lastname: Del Rio
authors.affiliation: Université François Rabelais, UMR 1100,  Tours, France.|INSERM, Centre d'Etude des Pathologies Respiratoires, UMR 1100, Tours, France.
authors.forename: Serge
authors.initials: S
authors.lastname: Guyetant
authors.affiliation: Université François Rabelais de Tours, CNRS, GICC UMR 7292, Tours, France.
authors.forename: Diana Carolina
authors.initials: DC
authors.lastname: Cadena Castaneda
authors.affiliation: Université François Rabelais de Tours, CNRS, GICC UMR 7292, Tours, France.
authors.forename: Christine
authors.initials: C
authors.lastname: Dhommée
authors.affiliation: Université François Rabelais de Tours, CNRS, GICC UMR 7292, Tours, France.
authors.forename: Christophe
authors.initials: C
authors.lastname: Arnoult
authors.affiliation: Department of Biochemistry and Molecular Biology, University of Athens, Panepistimiopolis, Athens, Greece.
authors.forename: Andreas
authors.initials: A
authors.lastname: Scorilas
authors.affiliation: Université François Rabelais de Tours, CNRS, GICC UMR 7292, Tours, France.|CHRU de TOURS, Laboratoire d'Immunologie, Tours, France.
authors.forename: Valérie
authors.initials: V
authors.lastname: Gouilleux-Gruart
authors.affiliation: Université François Rabelais, UMR 1100,  Tours, France.|INSERM, Centre d'Etude des Pathologies Respiratoires, UMR 1100, Tours, France.
authors.forename: Nathalie
authors.initials: N
authors.lastname: Heuzé-Vourc'h
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor; D002289:Carcinoma, Non-Small-Cell Lung / Q000276:immunology / Q000401:mortality*; D015536:Down-Regulation; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D015395:Histocompatibility Antigens Class I / Q000032:analysis / Q000235:genetics*; D006801:Humans; D008168:Lung / Q000737:chemistry; D008175:Lung Neoplasms / Q000276:immunology / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D016016:Proportional Hazards Models; D012333:RNA, Messenger / Q000032:analysis; D011961:Receptors, Fc / Q000032:analysis / Q000235:genetics*
chemical_list: D014408:Biomarkers, Tumor; D015395:Histocompatibility Antigens Class I; D012333:RNA, Messenger; D011961:Receptors, Fc; C100688:Fc receptor, neonatal
keywords: FcRn; antitumor immunity; marker; non-small cell lung cancer; prognosis